Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout

BMC Musculoskeletal Disorders

Volumn 13, Issue , 2012, Pages

  Dalbeth, Nicola ^a   House, Meaghan E ^a   Horne, Anne ^a   Petrie, Keith J ^a   McQueen, Fiona M ^a   Taylor, William J ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF OTAGO WELLINGTON   (New Zealand)

Author keywords

Allopurinol; Gout; Target; Urate

Indexed keywords

AGENTS AFFECTING METABOLISM; ALLOPURINOL; ANTIGOUT AGENT; ANTIINFLAMMATORY AGENT; COLCHICINE; CREATININE; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROBENECID; UNCLASSIFIED DRUG; URIC ACID; URIC ACID LOWERING AGENT;

ABSENTEEISM; ADULT; AGE; ARTICLE; BODY MASS; CREATININE CLEARANCE; CROSS-SECTIONAL STUDY; DISEASE ACTIVITY; DISEASE DURATION; DIURETIC THERAPY; ETHNICITY; FEMALE; GOUT; HEALTH BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCRIPTION; SEX DIFFERENCE; URIC ACID BLOOD LEVEL;

ADULT; AGED; ALLOPURINOL; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; DRUG DOSAGE CALCULATIONS; FEMALE; GOUT; GOUT SUPPRESSANTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; QUESTIONNAIRES; TREATMENT OUTCOME; URIC ACID;

EID: 84866160404     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-13-174     Document Type: Article

References (26)

1. Treating to target: a strategy to cure gout. Perez-Ruiz F, Rheumatology (Oxford) 2009 48 2 9 14
2. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, Schumacher HR, J Rheumatol 2001 28 577 580 11296962 (Pubitemid 32202663)
3. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Shoji A, Yamanaka H, Kamatani N, Arthritis Rheum 2004 51 321 325 10.1002/art.20405 15188314 (Pubitemid 38725128)
4. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A, Arthritis Rheum 2002 47 356 360 10.1002/art.10511 12209479 (Pubitemid 34856121)
5. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. Perez-Ruiz F, Martin I, Canteli B, J Rheumatol 2007 34 1888 1893 17659752 (Pubitemid 350067651)
6. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, Hingorani A, Jaques R, Nuki G, Rheumatology (Oxford) 2007 46 1372 1374 10.1093/rheumatology/kem056a
7. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Liote F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I, Ann Rheum Dis 2006 65 1312 1324 10.1136/ard.2006.055269 16707532 (Pubitemid 44620440)
8. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. Dalbeth N, Kumar S, Stamp L, Gow P, J Rheumatol 2006 33 1646 1650 16783857 (Pubitemid 44168841)
9. Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Roddy E, Zhang W, Doherty M, Ann Rheum Dis 2007 66 1311 1315 10.1136/ard.2007.070755 17504843 (Pubitemid 47492473)
10. Adherence with urate-lowering therapies for the treatment of gout. Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS, Arthritis Res Ther 2009 11 46 10.1186/ar2659 19327147
11. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD). Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Saag KG, Rheumatology (Oxford) 2005 44 1038 1042 10.1093/rheumatology/keh679 (Pubitemid 41487179)
12. Edwards NL, Quality of Care in Patients with Gout, Why is Management Suboptimal and What Can Be Done About It? Curr Rheumatol Rep: Curr Rheumatol Rep 2010
13. Patients and providers view gout differently: a qualitative study. Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA, Chronic Illn 2010 6 263 271 10.1177/1742395310378761 20675361
14. Uric acid lowering therapy: prescribing patterns in a large cohort of older adults. Solomon DH, Avorn J, Levin R, Brookhart MA, Ann Rheum Dis 2008 67 609 613 17728328 (Pubitemid 351571922)
15. High prevalence of gout in patients with Type 2 diabetes: male sex, renal impairment, and diuretic use are major risk factors. Suppiah R, Dissanayake A, Dalbeth N, N Z Med J 2008 121 43 50 18953386
16. Preliminary criteria for the classification of the acute arthritis of primary gout. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF, Arthritis Rheum 1977 20 895 900 10.1002/art.1780200320 856219
17. Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Dalbeth N, Petrie KJ, House M, Chong J, Leung W, Chegudi R, Horne A, Gamble G, McQueen FM, Taylor WJ, Arthritis Care Res (Hoboken) 2011 63 1605 1612 10.1002/acr.20570
18. The assessment of diabetes-related cognitive and social factors: the Multidimensional Diabetes Questionnaire. Talbot F, Nouwen A, Gingras J, Gosselin M, Audet J, J Behav Med 1997 20 291 312 10.1023/A:1025508928696 9212382 (Pubitemid 27268598)
19. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT, Arthritis Rheum 2011 63 412 421 10.1002/art.30119 21279998
20. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Spencer K, Carr A, Doherty M, Ann Rheum Dis 2012
21. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Rees F, Jenkins W, Doherty M, Ann Rheum Dis 2012
22. Patient related factors are also important in treating gout. Chandratre P, Roddy E, Mallen C, BMJ 2012 344 191 10.1136/bmj.e191 22235018
23. The patient's experience of gout: new insights to optimize management. Dalbeth N, Lindsay K, Curr Rheumatol Rep 2012 14 173 178 10.1007/s11926-011- 0228-0 22198831
24. Treatment adherence in patients with gout. Reach G, Joint Bone Spine 2011 78 456 459 10.1016/j.jbspin.2011.05.010 21724443
25. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Zhu Y, Pandya BJ, Choi HK, Arthritis Rheum 2011 63 3136 3141 10.1002/art.30520 21800283
26. Hyperuricaemia, gout, and diabetic abnormality in Polynesian people. Prior IA, Rose BS, Harvey HP, Davidson F, Lancet 1966 1 333 338 4159475